Indegene Limited
Book Built Issue IPO · NSE, BSE
- Price band
- ₹430 - ₹452
- Lot size
- 33 shares
- Issue amount
- ₹1,841.76 cr
- Total subscription
- 70.26×
- Opens
- 6 May 2024
- Closes
- 8 May 2024
- Allotment
- 10 May 2024
- Listing
- 13 May 2024
Offer at a glance
Issue overview
- Issue size
- 4,07,46,891 shares
- Face value
- ₹2 per share
- Minimum investment
- ₹14,190
- Fresh issue
- ₹760 cr
- Offer for sale
- ₹1,081.76 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,916
- Issue type
- Book Built Issue IPO
- Shares before issue
- 22,24,35,091
- Shares after issue
- 23,92,49,250
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 33 | ₹14,916 |
| sHNI | 14 | 462 | ₹2,08,824 |
| bHNI | 68 | 2,244 | ₹10,14,288 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs(10L +) | 8,760 | 1,08,020 |
| HNIs (2-10L) | 4,380 | 1,78,974 |
| RETAIL | 4,29,231 | 24,93,188 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 365.85 | 70,505.94 |
| RETAIL | 640.24 | 4,991.06 |
| HNIs 2+ | 91.46 | 3,937.7 |
| HNIs 10+ | 182.93 | 11,384.28 |
| EMPLOYEES | 13.39 | 88.13 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| EPS | 10.84 | 11.97 | 7.46 |
| ROE | 0 | 0 | 0 |
| ROCE | 0 | 0 | 0 |
| RONW | 18.23 | 25.02 | 21.57 |
| PRE IPO(PE) | 7.55 | 0 | 0 |
| POST IPO(PE) | 37.78 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Founded in 1998, Indegene Limited is a leading digital solutions provider for the life sciences industry, helping companies with everything from drug development and clinical trials to regulatory submissions and sales & marketing. The company offers a wide range of services through its Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions, along with expert consultancy. Its subsidiary, DT Consulting, specializes in guiding life sciences firms through digital transformation to enhance customer experiences. Indegene has also been recognized for its workplace excellence, winning the Platinum Level award at the 2023 Healthy Workplace Conference and Awards. With a global team of 5,181 professionals and 65 active clients across India, North America, Europe, China, and beyond, Indegene continues to deliver innovative and impactful solutions for the life sciences sector.
Strengths
- Deep Healthcare Industry Expertise: A large portion of the team has healthcare backgrounds, enabling the company to understand sector-specific challenges and deliver tailored, effective solutions.
- Use of Advanced Digital Technologies: Employs AI, machine learning, and advanced analytics to automate processes, boost efficiency, and provide innovative, high-value solutions for clients.
- Strong Trust Among Leading Biopharma Companies: Delivers high-quality services that have helped build long-term relationships with major biopharma clients, including the top 20 by revenue, demonstrating reliability and adaptability to evolving industry needs.
Risk factors
- Influence of Industry Shifts: Operating within the life sciences sector makes the company sensitive to changing regulations, evolving healthcare policies, and rapid technological advancements. Slower industry growth or rising competition could impact its revenue and profitability.
- Complex Revenue Structures: The company’s business model and revenue streams may be difficult for investors to interpret, potentially causing hesitation and affecting its ability to raise capital for future expansion.
Promoters
BCP Topco VII Pte. Ltd
Registrar & documents
Lead manager
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory, Securities (India) Private Limited, Securities (India) Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Aspen Block G4, 3 rd Floor, Manyata EmbassyBusiness Park, Outer Ring Road, Nagawara Bengaluru 560 045
+91 80 4674 4567
[email protected]Company website ↗Understanding INDGN IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.